Characteristics of adult patients with DLBCL who received CAR-T or alloHCT
| Characteristic . | CAR-T (N = 181) . | alloHCT (N = 403) . | P . |
|---|---|---|---|
| Median age, y (range) | 61.0 (21.9-80.0) | 56.7 (18.5-72.9) | <.01* |
| Male sex, no. (%) | 117 (64.6) | 261 (64.8) | 1.00† |
| Karnofsky performance score 90-100 | 79 (43.6) | 243 (60.3) | <.01† |
| HCT Comorbidity Index ≥ 3, no. (%) | 73 (40.3) | 189 (46.9) | .04‡ |
| Missing | 9 (5.0) | 7 (1.7) | |
| Median time from diagnosis to CAR-T or alloHCT (mo) | 34.1 (2.7-282.3) | 40.6 (3.2-340.5) | .12* |
| >12 mo | 175 (96.7) | 384 (95.3) | |
| Median time from prior autoHCT to CAR-T or alloHCT (mo) | 14.6 (3.2-268.7) | 15.5 (1.2-196.9) | .58* |
| >12 mo | 97 (53.6) | 208 (51.6) | |
| Graft source, no. (%) | N/A | ||
| Bone marrow | N/A | 40 (9.9) | |
| Peripheral blood | N/A | 363 (90.1) | |
| Donor type, no. (%) | N/A | ||
| HLA-identical sibling | N/A | 189 (46.9) | |
| Matched unrelated donor | N/A | 153 (38.0) | |
| Haploidentical related | N/A | 61 (15.1) | |
| Year of CAR-T or alloHCT, no. (%) | <.01‡ | ||
| 2012-2014 | 0 (0.0) | 201 (49.9) | |
| 2015-2017 | 2 (1.1) | 171 (42.4) | |
| 2018-2019 | 179 (98.9) | 31 (7.7) | |
| Disease status at CAR-T/alloHCT, no. (%) | <.01‡ | ||
| Complete remission | 9 (5.0) | 220 (54.6) | |
| Partial remission | 39 (21.5) | 103 (25.6) | |
| Resistant/untreated relapse | 122 (67.4) | 50 (12.4) | |
| Unknown | 11 (6.1) | 30 (7.4) | |
| Lymphodepleting chemotherapy, no. (%) | N/A | ||
| Cyclophosphamide | 1 (0.6) | N/A | |
| Cyclophosphamide + fludarabine | 180 (99.4) | N/A | |
| Bridging therapy use, no. (%) | 35 (19.3) | N/A | N/A |
| CIBMTR prognostic score, no. (%) | <.01 | ||
| Low (score 0) | 54 (29.8) | 212 (52.6) | |
| Intermediate (score 2,4,5) | 78 (43.1) | 148 (36.7) | |
| High/very high (score 6,7,9,11) | 49 (27.1) | 43 (10.7) | |
| Follow-up, median (range) (mo) | 13.0 (1.0-27.7) | 51.8 (0.2-98.6) |
| Characteristic . | CAR-T (N = 181) . | alloHCT (N = 403) . | P . |
|---|---|---|---|
| Median age, y (range) | 61.0 (21.9-80.0) | 56.7 (18.5-72.9) | <.01* |
| Male sex, no. (%) | 117 (64.6) | 261 (64.8) | 1.00† |
| Karnofsky performance score 90-100 | 79 (43.6) | 243 (60.3) | <.01† |
| HCT Comorbidity Index ≥ 3, no. (%) | 73 (40.3) | 189 (46.9) | .04‡ |
| Missing | 9 (5.0) | 7 (1.7) | |
| Median time from diagnosis to CAR-T or alloHCT (mo) | 34.1 (2.7-282.3) | 40.6 (3.2-340.5) | .12* |
| >12 mo | 175 (96.7) | 384 (95.3) | |
| Median time from prior autoHCT to CAR-T or alloHCT (mo) | 14.6 (3.2-268.7) | 15.5 (1.2-196.9) | .58* |
| >12 mo | 97 (53.6) | 208 (51.6) | |
| Graft source, no. (%) | N/A | ||
| Bone marrow | N/A | 40 (9.9) | |
| Peripheral blood | N/A | 363 (90.1) | |
| Donor type, no. (%) | N/A | ||
| HLA-identical sibling | N/A | 189 (46.9) | |
| Matched unrelated donor | N/A | 153 (38.0) | |
| Haploidentical related | N/A | 61 (15.1) | |
| Year of CAR-T or alloHCT, no. (%) | <.01‡ | ||
| 2012-2014 | 0 (0.0) | 201 (49.9) | |
| 2015-2017 | 2 (1.1) | 171 (42.4) | |
| 2018-2019 | 179 (98.9) | 31 (7.7) | |
| Disease status at CAR-T/alloHCT, no. (%) | <.01‡ | ||
| Complete remission | 9 (5.0) | 220 (54.6) | |
| Partial remission | 39 (21.5) | 103 (25.6) | |
| Resistant/untreated relapse | 122 (67.4) | 50 (12.4) | |
| Unknown | 11 (6.1) | 30 (7.4) | |
| Lymphodepleting chemotherapy, no. (%) | N/A | ||
| Cyclophosphamide | 1 (0.6) | N/A | |
| Cyclophosphamide + fludarabine | 180 (99.4) | N/A | |
| Bridging therapy use, no. (%) | 35 (19.3) | N/A | N/A |
| CIBMTR prognostic score, no. (%) | <.01 | ||
| Low (score 0) | 54 (29.8) | 212 (52.6) | |
| Intermediate (score 2,4,5) | 78 (43.1) | 148 (36.7) | |
| High/very high (score 6,7,9,11) | 49 (27.1) | 43 (10.7) | |
| Follow-up, median (range) (mo) | 13.0 (1.0-27.7) | 51.8 (0.2-98.6) |